Please join Aclaris Therapeutics for an in-person R&D Day in New York to discuss the Company’s progress in addressing therapeutic gaps in significant and growing immuno-inflammatory markets.

The event will highlight Aclaris’ development of kinase and immune pathway inhibitor franchises addressing therapeutically relevant, validated immune targets. Company leadership will also present:

• Advancements in Aclaris’ innovative discovery technology platform for small and large molecule discovery
• Insights into the Company’s potential best-in-class small and large molecule drug candidates
• Updates on Aclaris’ ongoing trials and future clinical plans
• Recent progress in developing next-generation small molecule inhibitors and bi-specific antibodies

More information and topics will be provided as the date approaches.

A live question and answer session will follow the formal presentation.